Edurne Luque-Michel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Edurne Luque-Michel has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- María J. Blanco-Prieto
University of Navarra
4 shared publications Ane Larrea
Institute of Nanoscience of Aragon (INA) and Department of Chemical, Engineering and Environmental Technology, University of Zaragoza, C/Mariano Esquillor, s/n, I+D+I Building, 50018 Zaragoza, Spain
2 shared publicationsEdurne Imbuluzqueta
2 shared publicationsVictor Sebastian
2 shared publications- Victor Sebastian
Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza 50009, Spain
2 shared publications Alberto Clemente
1 shared publication
Latest Publications
- 1 December 2017
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 42, 315-320
Visualization of hybrid gold-loaded polymeric nanoparticles in cells using scanning electron microscopy
- 1 December 2017
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 42, 315-320
Visualization of hybrid gold-loaded polymeric nanoparticles in cells using scanning electron microscopy
- Open Access
- 1 May 2017
- Published by Elsevier in Chemical Engineering Journal
- Vol. 316, 663-672
Efficient production of hybrid bio-nanomaterials by continuous microchannel emulsification: Dye-doped SiO2 and Au-PLGA nanoparticles
- 1 May 2017
- Published by Elsevier in Chemical Engineering Journal
- Vol. 316, 663-672
Open AccessEfficient production of hybrid bio-nanomaterials by continuous microchannel emulsification: Dye-doped SiO2 and Au-PLGA nanoparticles
- 7 July 2016
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 14 (1) , 75-92
Clinical advances of nanocarrier-based cancer therapy and diagnostics
Cancer is a leading cause of death worldwide and efficient new strategies are urgently needed to combat its high mortality and morbidity statistics. Fortunately, over the years, nanotechnology has evolved as a frontrunner in the areas of imaging, diagnostics and therapy, giving the possibility of monitoring, evaluating and individualizing cancer treatments in real-time. Areas covered: Polymer-based nanocarriers have been extensively studied to maximize cancer treatment efficacy and minimize the adverse effects of standard therapeutics. Regarding diagnosis, nanomaterials like quantum dots, iron oxide nanoparticles or gold nanoparticles have been developed to provide rapid, sensitive detection of cancer and, therefore, facilitate early treatment and monitoring of the disease. Therefore, multifunctional nanosystems with both imaging and therapy functionalities bring us a step closer to delivering precision/personalized medicine in the cancer setting. Expert opinion: There are multiple barriers for these new nanosystems to enter the clinic, but it is expected that in the near future, nanocarriers, together with new 'targeted drugs', could replace our current treatments and cancer could become a nonfatal disease with good recovery rates. Joint efforts between scientists, clinicians, the pharmaceutical industry and legislative bodies are needed to bring to fruition the application of nanosystems in the clinical management of cancer.
- 7 July 2016
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 14 (1) , 75-92
Clinical advances of nanocarrier-based cancer therapy and diagnostics
Cancer is a leading cause of death worldwide and efficient new strategies are urgently needed to combat its high mortality and morbidity statistics. Fortunately, over the years, nanotechnology has evolved as a frontrunner in the areas of imaging, diagnostics and therapy, giving the possibility of monitoring, evaluating and individualizing cancer treatments in real-time. Areas covered: Polymer-based nanocarriers have been extensively studied to maximize cancer treatment efficacy and minimize the adverse effects of standard therapeutics. Regarding diagnosis, nanomaterials like quantum dots, iron oxide nanoparticles or gold nanoparticles have been developed to provide rapid, sensitive detection of cancer and, therefore, facilitate early treatment and monitoring of the disease. Therefore, multifunctional nanosystems with both imaging and therapy functionalities bring us a step closer to delivering precision/personalized medicine in the cancer setting. Expert opinion: There are multiple barriers for these new nanosystems to enter the clinic, but it is expected that in the near future, nanocarriers, together with new 'targeted drugs', could replace our current treatments and cancer could become a nonfatal disease with good recovery rates. Joint efforts between scientists, clinicians, the pharmaceutical industry and legislative bodies are needed to bring to fruition the application of nanosystems in the clinical management of cancer.
- Open Access
- 16 November 2015
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 8 (12) , 6495-6506
A simple approach to obtain hybrid Au-loaded polymeric nanoparticles with a tunable metal load
A new strategy to nanoengineer multi-functional polymer–metal hybrid nanostructures is reported. By using this protocol the hurdles of most of the current developments concerning covalent and non-covalent attachment of polymers to preformed inorganic nanoparticles (NPs) are overcome. The strategy is based on the in situ reduction of metal precursors using the polymeric nanoparticle as a nanoreactor. Gold nanoparticles and poly(DL-lactic-co-glycolic acid), PLGA, are located in the core and shell, respectively. This novel technique enables the production of PLGA NPs smaller than 200 nm that bear either a single encapsulated Au NP or several smaller NPs with tunable sizes and a 100% loading efficiency. In situ reduction of Au ions inside the polymeric NPs was achieved on demand by using heat to activate the reductive effect of citrate ions. In addition, we show that the loading of the resulting Au NPs inside the PLGA NPs is highly dependent on the surfactant used. Electron microscopy, laser irradiation, UV-Vis and fluorescence spectroscopy characterization techniques confirm the location of Au nanoparticles. These promising results indicate that these hybrid nanomaterials could be used in theranostic applications or as contrast agents in dark-field imaging and computed tomography.
- 16 November 2015
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 8 (12) , 6495-6506
Open AccessA simple approach to obtain hybrid Au-loaded polymeric nanoparticles with a tunable metal load
A new strategy to nanoengineer multi-functional polymer–metal hybrid nanostructures is reported. By using this protocol the hurdles of most of the current developments concerning covalent and non-covalent attachment of polymers to preformed inorganic nanoparticles (NPs) are overcome. The strategy is based on the in situ reduction of metal precursors using the polymeric nanoparticle as a nanoreactor. Gold nanoparticles and poly(DL-lactic-co-glycolic acid), PLGA, are located in the core and shell, respectively. This novel technique enables the production of PLGA NPs smaller than 200 nm that bear either a single encapsulated Au NP or several smaller NPs with tunable sizes and a 100% loading efficiency. In situ reduction of Au ions inside the polymeric NPs was achieved on demand by using heat to activate the reductive effect of citrate ions. In addition, we show that the loading of the resulting Au NPs inside the PLGA NPs is highly dependent on the surfactant used. Electron microscopy, laser irradiation, UV-Vis and fluorescence spectroscopy characterization techniques confirm the location of Au nanoparticles. These promising results indicate that these hybrid nanomaterials could be used in theranostic applications or as contrast agents in dark-field imaging and computed tomography.